Spruce Biosciences, Inc.
SPRB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $5 | $10 | $0 | $0 |
| % Growth | -51.3% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $5 | $10 | $0 | $0 |
| % Margin | 100% | 100% | – | – |
| R&D Expenses | $46 | $49 | $35 | $31 |
| G&A Expenses | $15 | $13 | $12 | $11 |
| SG&A Expenses | $15 | $13 | $12 | $11 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $61 | $62 | $47 | $42 |
| Operating Income | -$56 | -$52 | -$47 | -$42 |
| % Margin | -1,143.4% | -515.3% | – | – |
| Other Income/Exp. Net | $3 | $4 | $1 | -$0 |
| Pre-Tax Income | -$53 | -$48 | -$46 | -$42 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$53 | -$48 | -$46 | -$42 |
| % Margin | -1,079.9% | -475% | – | – |
| EPS | -96.75 | -93 | -72 | -68.25 |
| % Growth | -4% | -29.2% | -5.5% | – |
| EPS Diluted | -96.75 | -93 | -72 | -68.25 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $5 | $2 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$53 | -$47 | -$46 | -$42 |
| % Margin | -1,072.8% | -469.5% | – | – |